This is a research study to check how safe and effective is Theoasthalin/ Theoasthalin forte tablets in patients with asthma and other chronic lung diseases.
- Conditions
- Health Condition 1: J00-J99- Diseases of the respiratory system
- Registration Number
- CTRI/2020/01/023000
- Lead Sponsor
- Cipla Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 168
1. A written, signed, dated and ethics committee approved informed consent form (data sharing consent) from Patients and/or legally acceptable representatives
2. Either male or female of age between 18 years and 60 years
3. Patients with reversible airflow obstruction associated with asthma and other chronic lung diseases suitable to receive either theoasthalin/theoasthalin forte tablets.
1. Patients with hypersensitivity to study drugs.
2. Patients with pregnancy or lactation.
3. Patients with Active peptic ulcer disease.
4. Patients with Seizure disorders.
5. Patients with Cardiac arrhythmias.
6. Concurrent diseases such as Acute pulmonary edema, Congestive heart failure, Cor pulmonale, Fever; �102 F for 24 hours or more; or lesser temperature elevations for longer periods, Hypothyroidism, Hyperthyroidism, Liver disease; cirrhosis, acute hepatitis, Sepsis with multi-organ failure, shock.
7. Patients on beta-blocking drugs.
8. Patients unsuitable for study as per Investigatorââ?¬•s discretion.
9. Participated in clinical trial 30 days prior to screening.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method